Better Therapeutics- Tradeable Rights - March 2021 OverviewTrack Better Therapeutics- Tradeable Rights - March 2021's operating income ($-30M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2023
Trailing 12 months ending Sep 30, 2023
As of the most recent data (September 2023), MCADR shows a operating income of $-30M. That compares with $-42M in the prior-year period — up 29.6% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, MCADR's operating income is now $-30M (was $-42M) — a 29.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Better Therapeutics- Tradeable Rights - March 2021 is outperforming or lagging.
Tracking MCADR's operating income over time shows whether Better Therapeutics- Tradeable Rights - March 2021 is scaling, shrinking, or reshaping that part of the business. The current reading is $-30M That compares with $-42M in the prior-year period — up 29.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this operating income page, Stockcircle has Better Therapeutics- Tradeable Rights - March 2021's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-30M) with ownership activity and broader fundamentals.
